Archive for the ‘Genetic Testing’ Category

FACTS AT A GLANCEEdition:9;Released:April 2021Executive Pool:383Companies:42 - Players covered include Alta Genetics, Inc.; Animal Genetics Inc.; Crv Holding B.V.; Envigo, Inc.; Ew Group GmbH; Genus PLC; Hendrix Genetics BV; Neogen Corporation; Vetgen; Zoetis, Inc. and Others.Coverage:All major geographies and key segmentsSegments:Product & Service (Live Animals, Genetic Materials, Animal Genetic Testing Services)Geographies:World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Complimentary Project Preview -This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass Platform which offers thousands of data bytes without an obligation to purchase our report.Preview Registry

ABSTRACT-

Global Animal Genetics Market to Reach $7 Billion by 2026Amid the COVID-19 crisis, the global market for Animal Genetics estimated at US$4.6 Billion in the year 2020, is projected to reach a revised size of US$7 Billion by 2026, growing at a CAGR of 7% over the analysis period. Live Animals, one of the segments analyzed in the report, is projected to record a 7.6% CAGR and reach US$5.1 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Genetic Materials segment is readjusted to a revised 6.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.5 Billion in 2021, While China is Forecast to Reach $1.2 Billion by 2026The Animal Genetics market in the U.S. is estimated at US$1.5 Billion in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2026 trailing a CAGR of 6.5% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.6% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.7% CAGR.

Animal Genetic Testing Services Segment to Reach US$836.6 Million by the year 2026In the global Animal Genetic Testing Services segment, USA, Canada, Japan, China and Europe will drive the 4.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$514.3 Million in the year 2020 will reach a projected size of US$696.9 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. More

MarketGlass PlatformOur MarketGlass Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide.

Our platform is free for qualified executives and is accessible from our website http://www.StrategyR.com or via our just released mobile application oniOSorAndroid

About Global Industry Analysts, Inc. & StrategyRGlobal Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years.

CONTACTS:Zak AliDirector, Corporate CommunicationsGlobal Industry Analysts, Inc.Phone: 1-408-528-9966www.StrategyR.com Email: [emailprotected]

LINKSJoin Our Expert Panelhttps://www.strategyr.com/Panelist.asp

Connect With Us on LinkedInhttps://www.linkedin.com/company/global-industry-analysts-inc./

Follow Us on Twitterhttps://twitter.com/marketbytes

Journalists & Media[emailprotected]

SOURCE Global Industry Analysts, Inc.

http://www.strategyr.com

Originally posted here:
New Analysis from Global Industry Analysts Reveals Steady Growth for Animal Genetics, with the Market to Reach $7 Billion Worldwide by 2026 -...

BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it has submitted its Type II variation application to the European Medicines Agency (EMA) for IMCIVREE (setmelanotide) for the treatment of obesity and control of hunger in adult and pediatric patients six years of age and older with Bardet-Biedl syndrome (BBS) or Alstrm syndrome.

This marks an important milestone toward our goal of delivering IMCIVREE globally to patients with BBS and, ultimately, many other rare genetic diseases of obesity, said David Meeker, M.D., Chairman, President and Chief Executive Officer of Rhythm. IMCIVREE achieved clinically meaningful and statistically significant results in our Phase 3 trial in BBS and provided evidence of marked and sustained weight loss in patients with Alstrm syndrome treated in our Phase 2 and 3 trials. Based on these data, we believe IMCIVREE will be the first medicine to effectively address the severe, early-onset obesity and hyperphagia that characterize these diseases. We look forward to working closely with regulatory authorities in the European Union to deliver IMCIVREE to these additional populations.

The BBS community in the EU is particularly well established, with approximately 1,500 patients diagnosed and being cared for at academic centers, said Yann Mazabraud, Executive Vice President, Head of International of Rhythm. Importantly, many of these patients present with the severe obesity and hyperphagia that treatment with IMCIVREE is designed to address. We are eager to continue our targeted efforts to increase understanding of BBS and the potential benefits of IMCIVREE and, if authorised, look forward to bringing this treatment to market quickly as a key step toward transforming the care of people living with rare genetic diseases of obesity.

The EMA submission is based on data from Rhythms pivotal Phase 3 clinical trial of setmelanotide in patients with BBS or Alstrm syndrome. The EMA submission is based on data from Rhythms pivotal Phase 3 clinical trial of setmelanotide in patients with BBS or Alstrm syndrome. As previously reported, the study met its primary endpoint and all key secondary endpoints, with statistically significant and clinically meaningful reductions in weight and hunger at 52 weeks on therapy. All patients who met the primary endpoint defined as more than 10 percent weight loss had BBS and none had Alstrm syndrome. However, data from this Phase 3 trial is supported by results from the Phase 2 trial, which suggest that treatment with setmelanotide may result in decreased weight and hunger in people living Alstrm syndrome. In addition, data from a predefined exploratory endpoint showed that, in BBS and Alstrm syndrome patients younger than 18 years old, setmelanotide treatment was associated with clinically meaningful reductions in BMI-Z scores. The BMI-Z score, or BMI standard deviation score, represents the number of standard deviations from median BMI by child age and sex.

About Bardet-Biedl and Alstrm Syndromes BBS and Alstrm syndrome are ultra-rare genetic diseases that affect multiple organ systems. Clinical features of BBS may include cognitive impairment, polydactyly, renal dysfunction, hypogonadism, and visual impairment. Clinical features of Alstrm syndrome may include progressive visual and auditory impairment, insulin resistance and Type 2 diabetes, hyperlipidemia, progressive kidney dysfunction, cardiomyopathy, and short stature in adulthood. Insatiable hunger, also known as hyperphagia, and severe obesity beginning early in life is common in people living with either BBS or Alstrm syndrome. Rhythm estimates that BBS affects approximately 1,500 to 2,500 people and that Alstrm syndrome affects approximately 500 people in the United States, with a similar prevalence estimate in Europe. Currently, there are no approved therapies targeting the MC4R pathway for reducing body weight and hunger in BBS or Alstrm syndrome.

AboutRhythm Pharmaceuticals Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity. Rhythms precision medicine, IMCIVREE (setmelanotide), was approved inNovember 2020by theU.S. Food and Drug Administration(FDA) for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing and in July andSeptember 2021, respectively, by theEuropean Commission(EC) and Great BritainsMedicines & Healthcare Products Regulatory Agency(MHRA) for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. IMCIVREE is the first-ever FDA-approved and EC- and MHRA-authorized therapy for patients with these rare genetic diseases of obesity. Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity, and is leveraging the Rhythm Engine and the largest known obesity DNA database -- now with approximately 37,500 sequencing samples -- to improve the understanding, diagnosis and care of people living with severe obesity due to certain genetic deficiencies. Rhythms headquarters is inBoston, MA.

IMCIVREE (setmelanotide) Indication In the EU andGreat Britain, IMCIVREE is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. IMCIVREE should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology.

Inthe United States, IMCIVREE is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. The condition must be confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).

Limitations of Use IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective:

Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign;Other types of obesity not related to POMC, PCSK1 or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity.

Important Safety Information

WARNINGS AND PRECAUTIONS

Disturbance in Sexual Arousal:Sexual adverse reactions may occur in patients treated with IMCIVREE. Spontaneous penile erections in males and sexual adverse reactions in females occurred in clinical studies with IMCIVREE. Instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.

Depression and Suicidal Ideation:Some drugs that target the central nervous system, such as IMCIVREE, may cause depression or suicidal ideation. Monitor patients for new onset or worsening of depression. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors.

Skin Pigmentation and Darkening of Pre-Existing Nevi:IMCIVREE may cause generalized increased skin pigmentation and darkening of pre-existing nevi due to its pharmacologic effect. This effect is reversible upon discontinuation of the drug. Perform a full body skin examination prior to initiation and periodically during treatment with IMCIVREE to monitor pre-existing and new skin pigmentary lesions.

Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in Neonates and Low Birth Weight Infants:IMCIVREE is not approved for use in neonates or infants.

ADVERSE REACTIONS

The most common adverse reactions (incidence 23%) were injection site reactions, skin hyperpigmentation, nausea, headache, diarrhea, abdominal pain, back pain, fatigue, vomiting, depression, upper respiratory tract infection, and spontaneous penile erection.

USE IN SPECIFIC POPULATIONS Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.

Treatment with IMCIVREE is not recommended for use while breastfeeding.

To report SUSPECTED ADVERSE REACTIONS, contactRhythm Pharmaceuticalsat +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

See Full Prescribing Information and EU SmPC for IMCIVREE.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the potential, safety, efficacy, and regulatory and clinical progress of setmelanotide, our expectations surrounding potential regulatory submissions, approvals and timing thereof, our business strategy and plans, including regarding commercialization of setmelanotide, and our participation in upcoming events and presentations. Statements using word such as expect, anticipate, believe, may, will and similar terms are also forward-looking statements. Such statements are subject to numerous risks and uncertainties, including, but not limited to, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks associated with data analysis and reporting, our liquidity and expenses, the impact of the COVID-19 pandemic on our business and operations, including our preclinical studies, clinical trials and commercialization prospects, and general economic conditions, and the other important factors discussed under the caption Risk Factors in our Quarterly Report on Form 10-Q for the quarterly period endedJune 30, 2021and our other filings with theSecurities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Corporate Contact: David Connolly Head of Investor Relations and Corporate Communications Rhythm Pharmaceuticals, Inc. 857-264-4280 dconnolly@rhythmtx.com

Investor Contact: Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.com

Media Contact: Adam Daley Berry & Company Public Relations 212-253-8881 adaley@berrypr.com

Recent Stories You Might Have Missed

Read the original here:
Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the European ... - Tyler Morning Telegraph

SAN DIEGO, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), developer of the Saphyrsystem that uses optical genome mapping (OGM) for the detection and analysis of structural variants (SVs), today announced the publication of a study in which OGM and next-generation sequencing (NGS) with linked-reads were used together to resolve genetic diseases that were previously unclassified after evaluation by whole-exome sequencing (WES) alone. This study, from the University of California, San Francisco (UCSF) and Childrens Hospital Oakland (now UCSF Benioff Childrens Hospital Oakland) and appearing in the September 23, 2021 peer-reviewed issue of Nature Publishing Journal of Genomic Medicine, shows the benefit of combining OGM with short-read sequencing for improved detection of clinically relevant variants in genetic disease research.

The studys authors, Shieh, et al., describe their Full-Genome Analysis (FGA) approach with automated analysis using NGS linked-read sequencing and OGM to evaluate a full spectrum of genetic variants found in inherited genetic diseases.FGA identified structural variants and small variants with an increase in detection capability of 40%(20 of 50 cases). The number of resolved cases attributable to SVs was notable in the study, as 50% of exome-negative cases (four of eight cases) were solved by identifying an SV or rearrangement. The authors also identified candidate variants in another 60% (18 of 30 cases) for future follow-up.

In one specific case, the authors found a rare 32kb heterozygous de novo intronic duplication within theNHEJ1gene that was not detected by standard microarray analysis because it was small and intronic. It had also escaped detection in copy number variants called from short-read, whole genome sequencing (WGS) data but was easily identified with their FGA method using OGM.

The findings reinforce that the combination of OGM and NGS used in the FGA method detects and localizes SVs such as duplications missed by WGS, and can quickly identify translocations and phase variants across long distances. For individuals with undiagnosed conditions, these two technologies encompass what is currently provided by the combination of chromosome analysis karyotyping, microarray testing and short-read WGS. FGA provides information beyond current assays and results in higher resolution genome maps that can be used for future studies.

As observed in the study, Bionanos Saphyr system, which can detect all classes of SVs, such as insertions, deletions, inversions, duplications, translocations and copy number variations, complemented NGS. Accordingly, when used together, they can provide the clinical research community with the ability to see the entire genome and identify a more comprehensive set of genetic variants to diagnose rare diseases accurately.

Erik Holmlin, PhD, CEO of Bionano Genomics, commented, This studys results go beyond just reinforcing the power of OGM it shows us how we can significantly impact peoples lives by combining NGS and OGM in genome analysis to find answers. Fifty percent of the participants in this study had clinically relevant variants hidden in their genomes that WES alone had not uncovered. OGM, together with a linked-read assay using NGS, revealed key answers for these participants. We believe there is tremendous potential in using OGM together with NGS to understand disease from the very beginning of any study. Congratulations to Dr. Shieh and his team on this tremendous progress.

This publication is available athttps://www.nature.com/articles/s41525-021-00241-5

About Bionano Genomics

Bionano is a genome analysis company providing tools and services based on its Saphyrsystem to scientists and clinicians conducting genetic research and patient testing; it also provides diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionanos Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables scientists and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano offers genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for more than nine years and has performed more than 65,000 tests for those with neurodevelopmental concerns. For more information, visitbionanogenomics.comor lineagen.com.

Forward-Looking Statements of Bionano Genomics

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the utility of the combination of OGM and NGS, including with respect to enabling the accurate diagnosis of rare diseases, and its potential benefits to the research community. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; observations from studies may not be replicated or have the anticipated benefits once implemented by the clinical research community; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated withour business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2020 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on managements assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com

Investor Relations:Amy ConradJuniper Point+1 (858) 366-3243amy@juniper-point.com

Media Relations:Michael SullivanSeismic+1 (503) 799-7520michael@teamseismic.com

See original here:
Study Shows the Combination of OGM and NGS with Linked-Reads Detects Significantly More Clinically Relevant Variants Resulting in Higher Success Rates...

video:A new GeneSight Mental Health Monitor national survey finds many Americans are experiencing anxiety symptoms, but some wont seek treatment. view more

Credit: GeneSight Mental Health Monitor

Many Americans are experiencing anxiety symptoms as a result of the pandemic. Yet, one in five say they wont seek treatment for mental health conditions and others say they wont get help until these symptoms take a toll in their lives.

Nearly half (46%) of all respondents rated their anxiety symptoms as moderate to severe over the past six months, according to the GeneSight Mental Health Monitor from Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine.

Of those surveyed who are diagnosed with anxiety, the numbers are even worse 86% rated their anxiety symptoms as moderate to severe over the past six months. While the pandemic is only 18 months old, more than half of those diagnosed with anxiety say they lived with symptoms for years or decades before seeking treatment.

For those who havent sought treatment but are concerned they may be suffering from anxiety, only 36% are planning to seek treatment. When asked what it would take to get help for their anxiety, 47% said a debilitating panic attack. Additional reasons included not being able to leave their homes (34%), sleep issues (31%), an unshakeable feeling of dread (30%) and a negative impact to relationships (30%).

Imagine waiting until you lose your hearing to treat an ear infection. Patients who are experiencing anxiety symptoms shouldnt wait to seek treatment, said Robin Miller, Internist, MD, MHS, owner of Triune Integrative Medicine in Medford, Oregon. If you are afraid to go out, experiencing panic attacks, cant sleep, or your relationships are suffering, you dont have to live like this. You don't have to wait. You don't have to suffer for years. Help is out there and treatment can help.

The impact of COVID on anxiety

Many American adults expressed concern regarding how the pandemic has impacted their mental health:

Mental health conversation is shifting

Of those diagnosed with anxiety, nearly half said they would feel more comfortable talking about their mental health today than they would a year ago.

The pandemic appears to have made people willing to share their mental health struggles, said Mark Pollack, MD, chief medical officer for Mental Health at Myriad Genetics. Talking about mental health challenges is the first step towards getting treatment.

Mental health disorders should be treated

While more people appear to be willing to talk about their mental health, one out of five respondents still say they wont seek treatment. The top reasons for those who would NOT seek treatment for a mental challenge are:

Untreated anxiety can be associated with distressing and disabling panic attacks, intense worry, and disruption to your life, work and relationships, said Dr. Pollack. Like other medical conditions, individuals should seek evaluation and treatment as early as possible, to minimize the distress and dysfunction associated with these conditions.

Anna, a 32-year-old mother who was first diagnosed with anxiety in her early 20s, said that seeking treatment wasnt easy. She went through an extensive trial-and-error period with different medications and dosages.

Medication seems to work fast in my body, so after taking a medication that was supposed to help me, my anxiety would instead get worse I would have suicidal thoughts and be paralyzed with worry, said Anna. My doctor would increase the dosage or change medications, which would lead to horrible side effects.

Anna then took the GeneSight test, which analyzes how a patients genes may affect their outcomes with medications commonly prescribed to treat anxiety, depression, ADHD, and other psychiatric conditions.

After reviewing the results of my test, my psychiatrist reduced the dose by half, and it helped me. I honestly dont know if I would have taken another medication if it hadnt been for genetic testing, said Anna. Im glad I pursued treatment until I found a medication and dosage that worked for me. Now that Im not riddled with crippling anxiety, everything has gotten better. Im a better mom. Im more motivated, more outgoing and friendly.

For more information on how genetic testing can help inform clinicians on treatment of depression, anxiety, ADHD, and other psychiatric conditions, please visit GeneSight.com. To download graphics, a multimedia video and other information regarding the survey, please visit https://bit.ly/2Y4qGri.

About the GeneSight Mental Health Monitor

The GeneSight Mental Health Monitor is a nationwide survey of U.S. adults conducted by ACUPOLL Precision Research, Inc. in Aug.-Sept. 2021 among a statistically representative sample of adults age 21+, including a representative sample diagnosed with anxiety. The margin of error in survey results for the total base population at a 95% confidence interval is +/- 3%.

About the GeneSight Test

The GeneSight Psychotropic test from Myriad Genetics is the category-leading pharmacogenomic test for 61 medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. The GeneSight test can help inform clinicians about how a patients genes may impact how they metabolize and/or respond to certain psychiatric medications. It has been given to more than 1.5 million patients by tens of thousands of clinicians to provide genetic information that is unique to each patient. The GeneSight test supplements other information considered by a clinician as part of a comprehensive medical assessment. Learn more at GeneSight.com.

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, EndoPredict, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries.

Read the original post:
Americans' anxiety impacted by the ongoing pandemic, yet 1 in 5 say they won't seek - EurekAlert

Genes are the basic units of inheritance in all living organisms. They provide cells with the necessary information for normal functioning, but they can be altered by the same environmental factors that cause cancer to develop.

Genetic testing helps identify specific genes that have mutated or been altered in a way that causes normal cells to become cancerous. These results are used by healthcare providers to predict responses to various types of treatment and monitor the progress of the disease. Genetic testing can refer to both germline testing (mutations in cells without cancer ) and also somatic testing of a patients tumor (mutations in cells with cancer).

What genetic testing means is understanding in a comprehensive way all the genetic abnormalities that may be present in one patients cancer that may not be present in others.

When examining genetic changes within tumor cells, researchers look for two main things:

These genetic abnormalities are what researchers are beginning to use as biomarkers for predicting patient responses to different forms of treatment.

In some families, bladder cancer occurs at higher rates than in the general population. In these cases, careful examination of the genealogy may reveal specific mutations passed from parent to child that may lead a medical provider to suspect one of the hereditary forms of bladder cancer. Some germline mutations linked to bladder cancer include:

While its possible, inherited gene mutations arent as commonly associated with bladder cancer as they are with other types of cancer, such as breast and ovarian. Sometimes, bladder cancer may occur in families because of toxic chemical or environmental exposures.

There are certain factors that increase an individuals risk for developing bladder cancer even if no family history exists. These include smoking and exposure to specific chemicals over long periods of time.

There are also inherited genetic syndromes that may place an individual at greater risk for developing bladder cancer. These include:

If genetic testing reveals you lack certain genes mutated in bladder cancer, you may be less likely to respond to certain treatments. These include targeted therapies, immunotherapies and chemotherapy drugs.

Genetic testing is not the only factor that determines your response to certain treatments. Even if your bladder cancer has all the genetic mutations that predict response to certain treatments, it still may not respond to them, because genetics is only one factor in determining a treatments effectiveness.

To increase the likelihood of response, bladder cancer treatments need to be combined with interventions designed to help your immune system target and kill cancer cells.

Genetic testing may also inform some decisions you and your medical team make as part of your ongoing care. If you are planning additional treatment after surgery or radiation, genetic testing may help determine the most appropriate treatment to use.

Genetic testing may be beneficial for many people with cancer. However, no guidelines exist to determine who should get genetic testing and the type of testing that should be done.

When I counsel a patient whos now undergoing their first treatment for advanced bladder cancer, Ill often encourage them to undergo genetic testing, mainly because we may find a genetic marker that is present in their cancer that might help me direct them toward a specific clinical trial that involves a drug that is specific for their genetic mutation, explains Dr. Balar.

Dr. Balar also recommends genetic testing for any patient with stage II or greater cancer. I advocate for early testing to have that information available early on so that if its needed, that information is readily available to make treatment decisions.

If youve been diagnosed with bladder cancer, talk to your healthcare team about the benefits and limitations of genetic testing.

Learn more about SurvivorNet's rigorous medical review process.

Lindsay Modglin is a freelance writer. Read More

Read more from the original source:
What Can Genetics Tell Us About the Molecular Features of a Bladder Cancer Tumor? - SurvivorNet

Everyone has 23 pairs of chromosomes, which include 22 pairs of autosomes and one pair of sex chromosomes. The science that relates to the study of these chromosomes is referred to as cytogenetics. Trained cytogeneticists examine the number, shape, and staining pattern of these structures using special technologies. In this way, they can detect extra chromosomes, missing chromosomes, missing or extra pieces of chromosomes, or rearranged chromosomes.

Chromosome Analysis (Karyotyping)

Karyotyping begins with placing cells on glass slides and separating whole chromosomes from thenucleiof the cells. The slides are stained with special dyes and examined under a microscope. Then, pictures are taken of the chromosomes on the slides, and the picture is cut into pieces, so the chromosome pairs can be arranged and matched. Each chromosome pair is assigned a special number (from 1 to 22, then X and Y) that is based on its staining pattern and size.

Examining a persons whole chromosomes, called karyotyping, can diagnose a wide array of disorders.Down syndrome, in which an individual has an extra chromosome 21, can be determined by karyotyping studies. When there are three chromosomes in one group instead of a pair, it is referred to as a trisomy. Missing chromosomes can also be detected, as in the case ofTurner syndrome, in which a female has only a single X chromosome. When there is only one chromosome instead of a pair, it is referred to as a monosomy.

Sometimes, a piece of a chromosome will break off and attach to another chromosome. When this happens, it is referred to as a translocation or rearrangement. For example,chronic myelogenous leukemia (CML)is a disease caused by a translocation in which a part of chromosome 9 breaks off and attaches itself to chromosome 22 (BCRABL-1 fusion gene). Another example is Burkitt lymphoma, in which a piece of chromosome 8 attaches to chromosome 14. These chromosomal translocations cause disease because the broken piece usually attaches to the new chromosome near a special gene that then becomes activated and helps to produce tumor cells. Translocations can sometimes be seen under the microscope if a special stain is used via karyotyping.

Fluorescence in situ hybridization (FISH)

A special technique commonly called FISH for short can be used to view changes in chromosomes that result from genetic variations. A gene segment in a chromosome can be made to light up or fluoresce when it is bound by a special probe. By using more than one probe at once, cytogeneticists can compare to see if the probes are located in their normal positions or if they have moved to a new location on a different chromosome, or if there are more or fewer copies of a probe than in a normal cell.

Genetic changes in some cancers can be detected using this method. For instance, FISH is one of the methods used to determine increased copy number (amplification) of the gene ERBB2 (also known asHER2) in breast cancer. There are many other applications of FISH technology as well, such as detecting chromosomal deletions, in which a certain part of a chromosome is completely missing. In this case, the chromosome segment will not fluoresce compared to a normal set of chromosomes.

More here:
Genetic Testing Techniques | Lab Tests Online

Helpful information about DNA TestingDNA 101: What Is DNA?

DNA stands for deoxyribonucleic acid, the name of a chemical chain that carries the genetic information of our parents and their parents, and so on. It contains the information needed to build different types of proteins that control different things in the body.

DNA is extremely complex.The rungs on the chemical chainstructured as a double helixare called base pairs, and theres over 3 billion of them across the 23 chromosome pairs in the nucleus of each cell in the human body (for a total of 6 billion over the 46 chromosomes). These base pairs make up about 20,000-25,000 genes, which instruct cells on how to build at least 90,000 proteins throughout all 30 trillion cells in the human body.

A single chromosome, therefore, contains hundreds to thousands of genes. A single gene can have anything from 27,000 to 2 million base pairs.

Chromosomes come in two types of pairs: autosomes, which are identical, as found in chromosomes 1-22), and allosomes, which can be different (as found in the 23rd pair). Allosomes determinethe organisms sex (everyone has one pair of these, either YX for males or XX for females).

DNA that comes from chromosomes is found in the nucleus of every cell, but this isnt the only type of DNA direct-to-consumer companies can use to identify ancestry. The mitochondria in cells also carry DNA. Unlike most nuclear DNA, mtDNA is passed practically unchanged from mother to child.

A common misconception is that DNA is like a blueprint for a human body. Instead, DNA chains are a coded list that instructs cells on how to build proteins. One of our interviewees, Professor Simon Fisher from the Max Planck Institutes Department Language and Genetics, sent us this handy explanation.

The human genomethe complete set of nuclear DNAis 99.9 percent identical for all humans. Its the 0.1 percentthat contains enough differences to make us into unique individuals. Understanding how information is passed on through genes, how genes instruct proteins, and how proteins translate into specific processes in the human body, can help us know ourselves better.

Scientists have identified that certain proteins are linked to specific conditions, diseases, or health risks. Certain proteins, for example, are responsible for the production of thehormone insulin. Mutations, changes, and variations in the genes that instruct cells to build this protein can cause a variety of disorders.

Different direct-to-consumer DNA companies have developed algorithms based on these variations. None of them analyze a persons entire, complex genome. Instead, they focus on markers or locations on the gene code that have been associated with certain populations or conditions.

Most commercial DNA kits offer two kinds of tests: ancestry and health.

Analyzing DNA is not as easy as reading a history book. Its not even as easy as reading science-heavy articles about the chemical composition of DNA.

In order to determine a persons ancestry, companies offer different types of tests:

Autosomal tests: these tests focus on autosomes 1-22 plus the X chromosome.

Y-DNA tests: these tests focus on the Y chromosome (if male), which is used to trace patrilineal ancestors because its passed practically unchanged from fathers to sons.

mtDNA tests: these tests focus on mitochondrial DNA, which is used to trace matrilineal ancestors because its passed practically unchanged from mothers to their children.

The autosomal DNA passed on by our parents is a mix of their DNA, and their parents DNA, and so on. The amount of ancestors doubles with each previous generation. That means DNA from only the last two hundred years can already be a mixture of 510 people (less if ancestors appear multiple times in a family tree).

Most ancestry testing, however, compares specific DNA markers (alleles) against those of existing, contemporary populations determined to have remained, historically, in the same place for a long time (each companys reference panel). A company like Ancestry, for instance, uses algorithms to find which ethnicity assignments return the highest probability matches.

This statistical matching, however, is limited by the natural genetic mixing that has historically occurred throughout many populations. Europeans, for example, are historically comprised of mixtures of populations from the region now known as Turkey, the ancient Roman Empire, and Northern Africa. Within the last 2,000 years, Britain alone has experienced immigration and genetic mixing from the Romans, various Germanic tribes, and the Middle East.

In a 2015 article, Jonathan Kahn, a law professor at Northeastern University who has written extensively on genomics and race, writesThe estimates provided by diverse commercial enterprises [...] are premised on a notion of static populations that have not migrated or mixed over time. [...But] the idea that there are somehow pure types of African, European, or Asian DNA is a ction [...]

This article in the American Journal of Human Genetics echoes that--[O]nly a small fraction of ancestors are represented by each given genomic segment in an individual, [...] so one can only ever have limited information on the origins of a given individual's ancestors. This is why some experts, like Professor Troy Duster from UC Berkeley, question the usage of admixture percentages, "Heres the problem in a nutshell. In order to have something called 'percent admixture'percent white, percent black, percent whatever, percent Italian, percent Jewishyoud have to have something called one hundred percent.

Direct-to-home DNA testing companies often use the term ethnicity when providing reports and statistical probability breakdowns for ancestry, health, and traits. Their usage of the term, however, varies, and it is often left undefined. AncestryDNAs White Paper, for example, does not define ethnicity in its glossary, but in its usage throughout, the term is synonymous with regions, populations, or even nationalities.

However, some have questioned the wisdom and utility of the term ethnicitya socially constructed concept based on self-identificationwhen discussing a biological component, DNA, especially in health contexts. Part of the difficulty arises from the often-contradictory nature of available definitions and its overlap with other socially-constructed and controversial terms like race.

This is further complicated by the facts that 1. there are no clear-cut ethnicities because most populations in the world are mixed to some degree, 2. socially constructed concepts like ethnicity and race have, historically, resulted in bias and discrimination, and 3. an overlap between modern ethnicity labels might not correspond to historical population names or locations.

DNA can certainly reveal a lot of information about where our genes come from. However, its important to understand that companies are only providing estimates based on DNA similarities to other contemporary populations. When an ancestry report says a person is 2% Scandinavian, it does not mean a specific, unique chunk of their DNA can come only from Scandinavia. Instead, what this percentage means is that certain portions of their genes have been statistically similar to those from contemporary Scandinavian populations.

This is why an individual can take multiple DNA tests from different companies or multiple tests with the same company, and get different results, and why identical twins have also been documented as having received slightly different reports.

The size of the databases also has to be taken into account. As Scientific American explains, several companies use both preexisting datasets as well as some reference populations that they have recruited themselves. ScienceNews.org cites anthropological geneticist Deborah Bolnick, saying, Who the companies say you aredependsin large parton those reference populations, Bolnick says. For instance, you may carry a pattern of SNPs found in people in both southern France and in Italy. If, by chance, the French people a company sampled had that SNP pattern but none of the Italians in the companys database did, they may infer that you have French ancestors and not Italian because of who they do and do not have in their database.

The Genetic Resource Center for the National Congress of American Indians explains the limitations of making probability estimates based on database comparison and the problem of using this to identify certain ethnic groups. [T]hese results are limited by the information in current databases, many of which do not contain a lot of information for particular groups (AI/ANs among them). This limitation in the data can produce problems for tribes and individuals seeking information as results may not be accurate or even possible to generate given limited availability of comparative data.

Companies like HomeDNA and African Ancestry are currently trying to address some of these limitations for African and Asian populations. As ScienceNews.org comments, some groups, including aboriginal populations in Australia and big parts of Africa and Asia, are mostly absent from companies databases.

Y-DNA and mtDNA are currently the most authentic and useful tests for ancestry, according to Dr. Troy Duster, professor of sociology at UC Berkeley. They are, as he told us, definitive and replicable. However, research suggests that lineage-based genetic estimates [...] reflect only a fraction of any person's total genetic ancestry.

Y-DNA tests can only trace one patrilineal ancestor at each generation because only one ancestor (a father) passed the Y chromosome to the next (his son). That means that, increasingly, at each further past generation, an individual has more and more ancestors that contributed to their genetic makeup, but which can't be reliably identified by tracing their genes.

Mitochondrial DNA tests are similarly limited; only the mothers mothers mothers mothers (etc.) mitochondrial DNA was passed on, meaning only one line can be traced. The paternal grandmothers line for any individual cannot be traced.

Like with ancestry testing, interpreting DNA in order to understand an individuals health risks, is a complicated business. Amy Sturm, president of the National Society of Genetic Counselors, explained how genetic analysis takes place."There is a reference for the normal human DNA code and, based on research that has been done looking at people with certain traits or conditions or diseases, we know that there are certain genes, that if they have a change in them a genetic variant that it would be associated with a certain trait or condition or disease. And so, with the DNA being analyzed in the laboratory, the scientists are looking for changes in the normal DNA code that they know is associated with a trait or condition."

She warns, however, that its usually not a simple 1-1 correlation because there are other genetic factors and environmental factors that likely play a role in that complexity, and we dont have all of those even have those figured out yet. Thus, whether a person takes a direct-to-consumer DNA test or a full test with a genetic counselor, its important they understand that it is more of a risk conversation.

The American Journal of Human Genetics highlights that the scientific claims of companies that choose not to disclose the contents of their proprietary databases cannot be assessed; therefore, the reliability of the information they provide to consumers cannot be verified. This is problematic because, as professor Duster told us in our interview, replicability is the key element in scientific study. However, some direct-to-consumer DNA testing companies are not opening this up to investigation by other scientists saying ok, you can come in and look at our data and see if you can do a replication study.

Ruth Saunders, a law graduate from Queen Mary University of London, echoes Dusters concerns in her 2010 article on the legal implications of DTC genetic testing and the lack of regulatory agencies enforcing scientific validity:The lack of regulation governing the quality of the genetic testing services is a serious concern because a genetic test is only useful to health when its analytical and clinical validity and clinical utility is assured.

Moreover, consumers should be aware that false-positive results can and do occur.

Commercial DNA testing companies often promote themselves through commercials that feature customers with uplifting stories and extremely happy results. Unexpected positive results are certainly one of the biggest draws of this industry, but its important to remember that they are not necessarily the norm.

One common thread across all of our interviewees was that it took a while for the interesting results to come up.

[At first], we just had the estimate genetics. And it was just like that for a while. And every once in a while, somebody would pop up, and it was a cousin that everybody knew, said Erin Dull, who found her half-sister through AncestryDNA.

Adam Lind, one of our employees, similarly described his own experience with AncestryDNA:

I got my results back at the beginning of March 2018. And at first, I was like, 0 for 1 there was no Native American, which is what I wanted to know. But there was a lot of UK DNA, like Irish and I didnt know that the Irish, specifically but there was English, Scottish, and some Western European. And I knew that I had a grandfather from Belgium. So, everything seemed copacetic.

Amy Sturm, president of the NSGC, gave us the following advice regarding managing expectations:

"There are many things people need to think about. You might learn something that youre not prepared to learn. You need to be prepared for this going in. You need to think through for yourself Am I the type of person that would prefer ignorance is bliss? Do I really not want to have family secrets unraveled or unveiled to me? And if so, you might not want to take one of these tests. It depends on the person. Its just something you really have to think about before you spit in that tube."

We spoke to three people who discovered that they had a half-sister, that their father was not their biological father, and that they were at risk of developing breast cancer. These are life-altering scenarios. That said, all three of our interviewees were happy to be aware of these truths about their DNA.

Erin Dull, who discovered her half-sister through AncestryDNA, told us: My life changed. Its the best thing that ever happened to me. Meeting my niece and nephew and having a sister is the greatest thing that ever happened to me.

Similarly, our colleague Adam describes his experience of finding his biological father positively: Hes as excited to know me as I am him. Theres this feeling of make up for the lost time. Im absolutely elated.

Our colleague Sara Altchule, who tested positive for the BRCA 2 gene mutation associated with breast cancer, said to us that, although it was a traumatic experience, she considered it to be the best decision I could have ever made. She documented her experience over several blog posts here.

Although we interviewed three people who experienced amazing or life-changing results, ranging from discovering close family members to a high predisposition towards conditions, this is not necessarily the common outcome. For example, another one of our employees who used 23&Me also commented that hed yet to receive any surprising or unexpected results despite having used the service several months ago.

Two common thread we found through our interviews were either the dont open that can of worms warning, or the if the connection is beyond 1st counsin, Im not interested admission. For example, Erin, one of our interviewees, told us of a friend who had used Ancestry to find her dad. Although he was glad to connect with her, some in the extended family were not, essentially saying we dont know you; youre not a part of this family; we dont want to talk about it.

Theres only one member of the family whos interested; the rest dont even want to talk about it. [One even warned] not to open that can of worms.

This warning is often associated with the potential discovery of family secrets or information that can create an "epistemological crisis,"as professor Duster put it. Not all biological parents want to be found, explores this article on the identity impact these tests can have and many are wary of. Indeed, Ancestrys support center has threads on managing surprising family members and regretting using the service.

On the other hand, some matched family might not want to reply or form a relationship because the connection is vague to them. Adam described his own experience:

The only reason I reached out was because it said father. I think, anything above 'first cousin,' and I would eventually reach out, but other than that, Im not interested. Like, someone who has an ancestor that neither of us has ever met? Im not interested. If someone reached out to me, I would email them back, but I had no interest in reaching out to anybody.

Personal identity is a complex concept influenced by many different factors. But concerns have been raised by experts in bioethics, sociology, anthropology, and genetics about the marketing claims of some DNA testing companies. Some ads for testing companies reinforce the link between DNA and identity, writes ScienceNews.org. For example, AncestryDNAs main page claims You could be Irish; 23&Me promises theyll help customers discover what makes you, you; MyHeritage boasts you can discover where you really come from.

Hina Walajahi, from the National Institute of Health, warns:

While this hyperbolic 'it-will-change-your-life' marketing strategy is not unique to DTC genetic ancestry companies, it is distinct in the way it draws upon public faith in science and scientific authority to validate a causal relationship between genetic ancestry and personal identity.

Prof. Duster explores the powerful draw of these claims:

People have a thirst to believe; theres a real desire to know ones ancestry. For example, because of the history of slavery and because their history was erased, many African Americans in particular have a strong interest in tracing their ancestry back to Africa, in ways people from Europe dont quite have that because they had grandmothers and grandfathers to tell tales about what percent ancestry there is and so on."

But some people are anxious and thirsty for this kind of information, so theyre inclined to believe it as true because thats what they want to believe. This can lead to epistemological crises about who they are.

These crises are not uncommon, as this testimony demonstrates. However, some, like Prof. Duster, challenge placing nature (DNA) above nurture, arguing that:

This notion that, somehow, the DNA that you discover your 'real' biological mother or father is who you really are is an extraordinary leap away from the idea that you are, in part, the social networks that brought you up and that are around you.

Our CEO, Greg Powel, puts it best:

"I think the notion of your self-conception evolves over the course of your life. Youre shaped by a combination of your experiences and the people around you and your genetic make-up and who you are. I think thats who we are as people."

As Amy Sturm from the National Society of Genetic Counselors wisely told us: DNA is not destiny.

Most major direct-to-consumer DNA testing companies have clauses in their Privacy Terms intended to assure customers that their genetic data will not be shared or sold without their consent. In an effort to ensure this, these companies anonymize customers DNA samples, removing identifiable information like name and address when the sample is sent to the lab.

However, experts warn that genomic data is highly distinguishable, and that even a sequence of 30 to 80 SNPs [single-nucleotide polymorphisms, a.k.a. markers or variations] could uniquely identify an individual. In other words, anonymized genetic data can be re-identified:

"[A]s demonstrated by multiple recent studies, the risk of re-identification is strongly present. It was shown, in multiple independent studies, that it is possible to learn the identities of people who participate in research studies by matching their data with publicly available data. Fida K. Dankar, et al. in Human Genomics."

In addition, many DNA matching services are unavailable or limited if consumers do not willingly give up some of their privacy. For example, Ancestrys DNA Matches reminds customers that if you choose not to see your DNA matches or be listed as a match, some of the features included in your Ancestry subscription may not be available.

Privacy and data security concerns have been raised by other consumers, the media, politicians, and experts. These range from genetic data being sold or shared with pharmacological companies for the development of pharmaceuticals, to the potential risks of health or life insurance companies obtaining consumers genetic information and using it to raise their premiums or deny them services. This is because genetic data provides sensitive information about genetic conditions and predispositions to certain diseases such as cancer, Alzheimer's, and schizophrenia.

In her article Privacy of Information and DNA Testing Kits,Shanna Mason points that that submitting to genetic tests are not only exposing themselves to the risk of their genetic information getting into the wrong hands, but are also exposing information about shared familial risk. Masons article explores topics like genetic discrimination, and where the HIPAA and GINA privacy laws come into play.

Nonetheless, consumers are responsible for keeping up-to-date with how privacy terms and conditions are changed or modified over time, and continuing to use the services is treated as acceptance of these changes.

Screenshot from 23andme.com's Terms of Service. August 20, 2019.

Screenshot from 23andme.com's Terms of Service. August 20, 2019.

Additional concerns have also been raised concerning several aspects of law enforcement, including, but not limited to, the use of DNA databases to potentially racially profile suspects, the use of DNA databases in forensics, laws that allow police and federal officials to retain DNA samples even from non-charged suspects or acquitted individuals, and the general wide misunderstanding in legal situations of the limits of genomics.

Consumers also should be aware that DNA companies are legally obligated to submit data and documentation if faced with a warrant or subpoena. Moreover, some companies are openly working in tandemwith law enforcement institutions, and there arent any regulations to stop it.

Many direct-to-consumer DNA kits have expiry dates because of the stabilizing solution they contain. This solution or buffer is what prevents bacterial contamination during the shipping process.

Expiry dates are different for different companies, be it because theyre being overly cautious, or because their kits have longer lifespans than others. Of the ones we used with our DNA volunteers, only AncestryDNA did not have a clear expiry date on the kit itself. Those that did had very different dates, even though we requested them all at the same time:

We recommend that customers mail in their DNA samples at least within a year of receiving their kits in the mail.

Read more:
Top 10 DNA Testing of 2021 | ConsumersAdvocate.org

Research of family registries found that individuals with a germline pathogenic ATM variant gene had greater lifetime risk of developing pancreatic cancer than individuals without the gene.

Individuals with a germline pathogenic ATM variant appear to have an increased lifetime risk of developing pancreatic cancer compared with those without the variant, according to findings from a multicohort study of pancreatic cancer family registries published in JAMA Oncology.

Pancreatic cancer cumulative risk for individuals with the germline pathogenic ATM variant was estimated by age increased from 0.08% (95% CI, 0.07%-0.09%) at 30 years to 0.30% (95% CI, 0.25%-0.36%) at 40 years, 1.08% (95% CI, 0.83%-1.33%) at 50 years, 3.03% (95% CI, 2.12%-3.94%) at 60 years, 6.28% (95% CI, 3.90%-8.66%) at 70 years, and 9.53% (95% CI, 5.04%-14.02%) at 80 years.

These findings underscore the need to develop appropriate surveillance and intervention strategies for these individuals at high-risk of developing pancreatic cancer, the investigators wrote.

The study enrolled kindreds who were included in family registries participating in the Pancreatic Cancer Genetic Epidemiology Consortium, which included the National Familial Pancreas Tumor Registry from Johns Hopkins University, the Biospecimen Resource for Pancreas Research from the Mayo Clinic, GI Cancer Genetics from Dana-Farber Cancer Institute, and the Ontario Pancreas Cancer Study from Mount Sinai Hospital, University of Toronto.

In order to be eligible, families were required to have at least 1 member who had been diagnosed pancreatic cancer and 1 family member with a germline ATM pathogenic variant.

Study population included 2227 individuals from 130 families. Notably, 95% of families were white and 49% of patients were women. The patient population had a mean age of 58 years. Of this population, 155 individuals returned a positive test result for an ATM pathogenic variant.

Although an increased prevalence of pancreatic cancer was seen among individuals not carrying the variant compared with untyped individuals, this was due to preferential genetic testing of patients with cancer over cancer-free individuals. Although other pedigree members had a missing pancreatic cancer status and/or age, they were included in order to complete the family structure; this was believed to have had a limited influence on estimated risk.

Within the families included in the study, 217 individuals had pancreatic cancer. Moreover, 78 families had 1 member with the disease, 34 families had 2 members, and 18 families had 3 or more members. Patients were an average of 64 years of age (range, 31-98) upon being diagnosed.

To determine whether there were findings to support penetrance differences between men and women, sex specific penetrance was examined. However, the study model did not appear to be significant ( = 0.12; SE, 0.11; P = .29). Compared with individuals without the ATM variant, the relative risk estimate of pancreatic cancer was 6.5 (95% CI, 4.5-9.5) for individuals with the ATM variant.

Compared with studies that have estimated a 2.2- to 6.6-fold increased risk of pancreatic cancer in BRCA2 variant carriers, the risk estimates of the present study strongly support inclusion of ATM variant carriers in screening trials, the investigators wrote.

The main limitation of the research centered around the European ancestry, which encompassed the majority of families included in the study population. The investigators suggest that future studies focus on non-European populations to better understand the risk of germline ATM variants.

Hsu FC, Roberts NJ, Childs E, et al. Risk of pancreatic cancer among individuals with pathogenic variants in the ATM Gene. JAMA Oncol. Published online September 16, 2021.doi:10.1001/jamaoncol.2021.3701

Read more:
Individuals With Pathogenic ATM Variant Have an Increased Lifetime Risk of Developing Pancreatic Cancer - Cancer Network

Theres growing concern about genetic discrimination in New Zealand and the lack of Government intervention in this fast-moving field.

As genetictesting becomes more accessible than ever before, there are calls for a line in the sand to be drawn and a final answer toaquestionnot yet canvassed: should insurers be able to use our geneticinformation?

Genetic discrimination is using someones genetic information to discriminate against them to treat them in a way thats different to someone else because we know something about their genetics.

Currently,lifeand health insurance companies in New Zealand are allowed to use thisdatain determining coverand premiumsfor applicants something experts sayanecdotalevidence suggest hasledto increased premiums, or no cover at all.

While insurers may argue it's their right to know a person's medical history researchers say genetics is, in fact, not a part of one's history, but a part of their future.

There are a lot of complexities in determining someone's genetic makeup and whether they are prone to getting a disease later in life.

There are also ways to mitigate and change the outcome of a patient's health once becoming privy to this information. For example, getting a mastectomywill drastically limit the chances of getting breast cancer, but there are fears an insurer may refuse cover based on a positive BRCA gene test regardless.

University ofOtago law and bioethics lecturerDr Jeanne Snellingsaysif people do have the test,and its positive, they can do things tominimisedevelopment of the disease.

They can undergo surveillance, get prophylactic preventative treatment and their risk could be quite similar to someone elses in the end. But, the insurance company is taking this absolutist approach saying that a positive test disqualifies you from obtaining life insurance cover.

There aredoubts about whether an insurance company would have staff with the expertise on hand to dissect someones genetic information.

University of Aucklands Faculty of Medical and Health Sciences Professor Andrew Shelling says it usually takes acastofspecialists to trawl through the data of an entire persons genome.

Good luck to the insurance company if they can find something, let us know. Because we have an entire team of experts from the clinicians to thebioinformaticiansto the geneticists who sit in a multi-disciplinary clinic each week trying to discuss the outcomes of what theyre looking at.

Based on the increased complexity of genetic testing nowadays, there is also a risk of getting it wrong if you dont have the right expertise. Hesaid.

There'salsoconcernpeople will not opt for undergoing genetic testing purely based on the fact it could be used by insurers -- and thus, miss out on the opportunity to decreasefuturehealth risks.

Despite the life-saving prevention available through genetic testing, experts say people avoiditand research because they are afraid of insurance discrimination.

This not only limits what a person can do to better their health in future -- but stunts medical research, particularly in minority groups like Mori and Pasifika, whose genetics are an even greater enigma to researchers than Pakeha.

Professor Shelling says we know that Mori have been discriminated against for years and this may be another form of it.

We base a lot of our genetics on European DNA, so for our Mori and Pasific people we dont always know what their results mean in a clinical setting.

We have an extra responsibility as genomic scientists to support Mori and Pasific getting genetic testing and make sure they dont get further discriminated against.

In a lot of our research studies around New Zealand, we are trying to increase the number of Mori and Pasific participants.

He fears if they have any concerns about insurance, theyllturn away from being part of these studies.

It's a conflict Jane Tiller anethical, legal and social advisor for Public Health Genomics at Melbournes Monash University --has battled for five years in Australia where a moratorium's been put in place to try and curb the issue.

Now, in Australia, you can get life insurance up to $500,000. If you try and take out more, you have to then disclose your genetic test results. she said.

She says the moratoriums a good step towards consumer protection but its a fraught approach.

"It goes up to certain financial limits and is only five years. So, we dont know what will happen in 2024 when it ends.

We are still gathering data about how its [the moratorium]working. Were remaining concerned about the lack of Government regulations on this issue.We would like to see a complete ban, like in Canada.

The moratorium isalso self-regulated by the insurance industry.

Self-regulation has been shown to be conflicted and problematic, both in Australia and New Zealand.

Theres very little transparency on how insurance companies use this data.Because this is self-regulated, theres a lot of questions around how decisions are made and what data is relied on.

The newly formed AGenDA (Against Genomic Discrimination Aotearoa) group, is lobbying for Government attention on this issue.

AGenDasmessage is that genetic discrimination is not only aconsumer protection issue, but a human rights issue.

Theysay itsnot just about making sure insurers get the information they need todiscriminate; its about stopping them from discriminatingaltogether. Its about ensuring consumers can make decisions about healthcare and learn empowering information without fear of discrimination for themselves or their family members.

They say thesectorhas come to presume divulgence -- an expectation thats been born of our insurance industry over many years.

The Financial Services Councils Richard Kiplin says its not something companies will ask for but if a client has information, it's only fair that they disclose it.

Within the New Zealand sector organisation by organisation will make their own calls. he said.

Whats important for New Zealand consumers to understand is that this is a complex area, and life companies need to assess risk and theyll do that in an appropriate way.

Genetic testing,at this point of time, is not a standard part of that -- but thats obviously evolving and moving very fast.

I think if people have had a genetic test and have information then they know information that a life and health company would want to understand. And so thats a part of the disclosure process.

Kiplin says hes open to working with researchers and other parties in future to solidify guidelines around genetic testing.

We have a robust committee structure thats been looking at some of these issues and reviewing guidelines.

The sector is never static, theres always stuff you can change and this is one of the big areas of the future.Hesaid.

AGenDAis alsoconcerned at the lack of Government intervention.

The Minister of Commerce and Consumer Affairs David Clark points towards the Ministry of Business, Innovation and Employment's Insurance Law Review.

"Insurer use of genetic testing results is one of many issues raised with MBIE during the course of the review, but it was not highlighted as a significant issue in the submissions (it was mentioned in two out of around 500 submissions received). Hesaid.

Clark mirrors the industrys openness to work with experts to understand the situation better.

Im told, the industryhavepreviously told my officials they are not seeing high levels of genetic testing, but I am open to further briefings on the matter.

The MBIEreview was promptedto ensure New Zealands insurance contract law is facilitating insurance markets that work well and enable individuals and businesses to effectively protect themselves against risk.

In November 2019 the Government agreed tothereform which includesmaking sure insurers ask consumers the right questions, the requirement for policies to be written and presented clearly, strengthening protection for consumers against unfair terms and extending powers to the Financial Markets Authority to monitor and enforce compliance.

Next steps for the review include release of an exposure draft Bill for consultation in late-2021.

Genetic testing has been described asa quantum leap for healthcare. A new kind ofapparatuswe can use to decode our future health.

In July 2021,the World Health Organization (WHO) provided the first global recommendations to help establish human genome editing as a tool for public health, with an emphasis on safety, effectiveness and ethics.

While their concerns are mainly based around the use of genetics to edit our DNA --WHO Director-General,Dr Tedros Adhanom Ghebreyesus, recognisedgenome editing and testing as a potential to advance our ability to treat and cure disease.

"But the full impact will only be realized if we deploy it for the benefit of all people, instead of fueling more health inequity between and within countries,Hesaid.

In September, the WHOrecommended DNA testing as a first-choice screening method for cervical cancer prevention.

It recognised DNA-based testing for human papillomavirus (HPV) has been shown to be more effective than todays commonly used screening methods aimed at detecting and preventing cervical cancer, a major cause of death among women worldwide.

Asgenetictestingbecomesmore mainstream,as the technologies mature,and as testsbecome moreprecise and affordable-- it evolves from being aniche offering tobecomingilluminatedon healthcarescentrestage.

And whilegenetictesting is applauded for its potential to become a part of our everyday health toolbox one question remains:should insurers be able to use our genetic information?

Read the original post:
Genetic discrimination: The next great health battle likely to wash up on NZ shores - Newstalk ZB

Nearly 1 in 5 adults in Georgia battle mental illness each year

SMYRNA, Ga., Oct. 5, 2021 /PRNewswire/ -- Ridgeview Institute is modernizing the standard of care for behavioral health treatment for Georgians in need of mental health and addiction services, thanks to a new partnership with GeneSight.

Ridgeview Institute - Smyrna

The GeneSight test, offered through Myriad Genetics, Inc. (NASDAQ: MYGN), helps clinicians understand how a particular individual may respond to certain medications by analyzing how a person's genes impact how they may break down or respond to medications commonly prescribed to treat depression, anxiety and other psychiatric conditions.

"Making GeneSight available for patients seeking mental health and addiction treatment is a game-changer in behavioral therapy," said Amy Alexander, CEO, Ridgeview Institute. "Every patient's mental health journey is different, which means their treatment plan needs to be, too. Knowing which medication a patient may respond to before they start treatment can help create a customized treatment plan that can increase response, reduce trial and error and minimize side-effects."

According to the latest federal data, nearly one in five adults in Georgia battle mental illness in any given year, with nearly half a million having at least one major depressive episode. According to one study, fewer than 50% of patients with depression respond to their first prescribed medication, and with each failed medication plan, their response to the treatment may decrease.[1] The process of finding the right medications that work is often frustrating, time-consuming and debilitating.

Ridgeview Institute is the only program of its kind in Georgia that has committed to offering the GeneSight test to every patient participating in outpatient services. Ridgeview Institute believes that everyone deserves to know that GeneSight is an option and an additional tool that may help them in their mental health journey.

Story continues

More than 1.5 million patients have used GeneSight to shed light on which medications may be better suited to their treatment and answer questions around why previous medications may not have worked.

The value of GeneSight is already being seen at Ridgeview Institute, contributing to a positive increase in patient outcomes. One patient saw results only one week after genetic testing. The patient was having sleep issues and not spending time with family. She was so tired that she slept for 12 hours every night and woke up fatigued, affecting her relationship with her kids and spouse. After using GeneSight, the clinic adjusted medication and reported seeing a noticeable improvement. The patient now stays up later, enjoys time with her family, and does not feel as fatigued. There is also a noticeable change in her appearance, and the patient is more energetic and upbeat.

"Science is used in all other areas of health to guide treatment, including x-rays, MRIs and blood work. It's a natural fit for genetic testing to be used in helping to customize behavioral therapy treatment," said Alexander. "We're excited by the potential this will have in helping even more Georgians get the help they need."

Ridgeview Institute has been Georgia's first choice in mental health and addiction treatment since 1976. Offering a comprehensive array of programs for youth, young adults, adults, and senior adults, the treatment facility also provides specialized programs for women and licensed professionals who need behavioral health and/or addiction intervention. It also offers the Recovery Residence, apartment-style living for those that are participating in PHP programs, which eliminates distance and transportation obstacles in a person's recovery.

Ridgeview Institute offers free assessments and individuals can be admitted directly into the program or referred after an acute inpatient hospitalization. For more information, please call 844-350-8800, 24 hours a day.

About Ridgeview Institute at Smyrna Since 1976, the mission of Ridgeview Institute has been to provide outstanding care, compassionate people, and unparalleled service, offering a full continuum of inpatient and outpatient mental health and substance abuse treatment to patients in Georgia. Since its founding, Ridgeview Institute at Smyrna has supported over 90,000 patients from Georgia and surrounding areas in mental health and substance use recovery. The suburban Atlanta campus offers patients a safe and serene environment and provides specialized, evidence-based behavioral health and substance use disorder treatment. http://www.ridgeviewinstitute.com/smyrna

[1] 1 Rush AJ, et al. 2006 Am J Psychiatry

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/ridgeview-institute-elevates-standard-of-care-in-behavioral-health-treatment-for-georgians-through-new-partnership-with-genesight-301392674.html

SOURCE Ridgeview Institute - Smyrna

Visit link:
Ridgeview Institute Elevates Standard of Care in Behavioral Health Treatment for Georgians Through New Partnership with GeneSight - Yahoo Finance

By JOYANNA LOVE/ Managing Editor

A breast cancer diagnosis was no surprise for Jeannie Smith.

In fact, she had been expecting it for 13 years, ever since her mother passed away.

My mom passed from breast cancer when she was 45, Smith said. I was 23 when she passed, and she had a very aggressive type of breast cancer.

That was in 2000. Back then, Smith said genetic testing for cancer was not available.

For 13 years, I waited and wondered because in my mind, I knew it wasnt a matter of if, it was a matter of when, Smith said.

She said she lived in fear and did daily self-examinations.

When health insurance companies started covering genetic testing for the BRCA1 mutation linked to breast cancer, Smith had it done.

I felt strongly that my mom had that mutation, so if she had that mutation, then there was a 50% chance that I had that mutation, Smith said.

She was tested in August 2014, which confirmed she had the BRCA1 mutation. Once this was confirmed, Smith began the process to have preventive surgery a double mastectomy. Smith said those with the mutation have an 87% chance of developing breast cancer in their lifetime, compared to the normal population of 11% in their lifetime.

Knowing how she had anticipated being diagnosed with cancer, her husband and family were supportive of the decision.

Three weeks before the surgery, she had a normal mammogram, but she said tumors often do not show up on a typical mammogram for younger women who have dense breasts.

As a part of routine pre-surgery procedures, a breast MRI was done.

When the phone rang soon after, she knew before she answered that it would be the doctor telling her she had cancer.

She was right.

Her children were ages 16, 10 and 9 when she was diagnosed. Smith said she was afraid that her children would have to go through what she had, losing her mom to cancer.

I was bitter, angry, Smith said. Cancer had already taken so much from me.

However, after a few days, she said God gave her peace.

I woke up the morning of the biopsy in total calmness, Smith said.

She took a sheet of scripture verses with her to help.

Throughout her 13 years of wondering, Smith said she was able to be educated and be very proactive about my health because of the American Cancer Society.

Smith was a volunteer with the Relay For Life of Chilton County, prior to becoming a staff member with the organization.

After mom died, I needed to do something to deal with the grief, something to give back or fight back for her make her death mean something, Smith said.

She said she fell in love with Relay for Life. Later, she worked in various positions for ACS moving into management until 2020.

The organization helped her to know her risk factors and keep up with research and know what I needed to do to stay ahead of the game.

There was even a researcher that was funded by the American Cancer Society that discovered the BRCA gene, Smith said.

Smith had the planned surgery, but now she also had to do four rounds of chemotherapy. Smith said because her cancer was in stage one, and she had a mastectomy, she was uncertain they would do chemotherapy. However, she wanted to have it done just to give her the best chance.

I knew I did not want to be facing this later on, Smith said. I wanted to hit it head on while we had the best chance possible of taking care of everything.

She wrote out three pages of reasons why she wanted it, but did not need it because her doctor had already decided chemotherapy would be a good option.

Smith had the surgery to remove her breasts and DIEP reconstructive surgery on the same day.

She explained that this type of reconstructive surgery takes fatty tissue and vessels and veins from your abdomen and use it to make your breast.

At the time there were only about 80 doctors in the U.S. that were able to do that type of surgery I chose that because it meant no implants, and it meant not having to have repeat MRIs every so many years, Smith said.

Since her cancer was estrogen fed, Smith knew she was at a higher risk of ovarian cancer, so she had a hysterotomy.

She now takes an anti-cancer pill that she will have to take for a total of 10 years.

She has also had some skin cancer treated in that time.

Smith said her cancer journey was turned into a blessing.

I am much stronger now than I ever thought I could be, Smith said. I have drawn closer to my Savior, stronger in my faith. I have been given the opportunity, especially when I was with the American Cancer Society to talk with newly diagnosed patients and caregivers. I had been in both of those roles, so I could relate the opportunity to be that voice of hope.

She said the technology and research has come so far from when her mother was diagnosed, and today, a breast cancer diagnosis does not have to be the end.

Read this article:
Fear turned to peace for breast cancer survivor Jeannie Smith - The Clanton Advertiser - Clanton Advertiser

An influential Genetic Testing market research report is very indispensable in many ways for business growth and to thrive in the market. This market report looks over the market with respect to general market conditions, market improvement, market scenarios, key developments, cost and profit of the specified market regions, brand position and comparative pricing between major players. In addition, businesses can be well acquainted with the level of the marketing problems, reasons for failure of particular product already existing in the market, and prospective market for a new product to be launched. This report offers a clear understanding of the present as well as future scenario of the Genetic Testing industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. To understand the market in depth, market research report is the perfect solution. Genetic Testing market document is right there for the same which lets know that how the market is going to perform in the forecast years by giving information about market definition, classifications, applications, and engagements.

Genetic testing market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to reach at an estimated value of 585.81 billion and grow at a CAGR of 11.85% in the above-mentioned forecast period. Increase in incidences of genetic disorders and cancer drives the genetic testing market.

Download Free Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-genetic-testing-market&AS

The Major Players of the Genetic Testing Market Are:

xx

Genetic Testing Market Segmentation:

By Type (Predictive & Presymptomatic Testing, Carrier Testing, Prenatal & Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Others)

By Technology (Cytogenetic Testing, Biochemical Testing, and Molecular Testing)

By Application (Cancer Diagnosis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, Others)

By Disease (Alzheimers Disease, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntingtons Disease, Rare Diseases, Other Diseases)

By Product (Equipment, Consumables)

Read complete report along with TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-genetic-testing-market&AS

The Full Report Includes

Enquire for customization in Report @: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-genetic-testing-market&AS

Key questions answered in the report:

Genetic Testing Market Country Level Analysis

About Data Bridge Market Research Private Ltd:

Data Bridge Market ResearchPvt Ltdis a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:Corporatesales@databridgemarketresearch.com

Read more from the original source:
Genetic Testing Market 2021 |Global Industry Analysis By Trends, Size, Share, Company Overview, Growth And Forecast By 2028 The Manomet Current - The...

STRONGSVILLE, Ohio (WJW) Paisley Palmer, 1, dances every morning when she wakes up.

She loves to make people laugh, adores animals and is an expert at blowing kisses.

Her parents say shes an inspiration and a bright light in their lives during a dark time; the active and happy little girl was diagnosed with Acute Myeloid Leukemia in July.

It all started in March, when her mom, Jessica, noticed what looked like a bruise on the right side of her face. She attributed it to the normal bumps toddlers get when theyre active and learning how to walk.

But the mark didnt go away.

It started changing in appearance, said Jessica. It started getting larger, you could actually feel it on the side of her face.

She and her husband, Tim, took Paisley to her pediatrician. After more doctors, ultrasounds and a biopsy, she was diagnosed with AML. Genetic testing also indicated it is a high-risk form of cancer.

Immense shock to us, many emotions during that time, said Jessica. She has never once appeared sickly. Thats really been a bit of a blessing for us. Shes always been so energetic, happy, running around, dancing, making as many friends as she can.

Paisley started treatment at UH Rainbow Babies and Childrens Hospital on Aug. 17. Shes currently on round 2 of what will be four to five rounds of chemotherapy.

After that, because she is high-risk, Paisley will then have to undergo bone marrow transplants. Jessica and Tim were shocked to learn they couldnt be donors. They turned to Be the Match registry for help.

Be The Match, which is operated by the National Marrow Donor Program, plays a role in every bone marrow cell transplant in the United States by matching donors in its registry to patients who need the transplants.

The transplants can be cures for patients like Paisley, who have blood cancers or other diseases or disorders.

Its really wild to me that my husband and I are only a 50 percent match to our little girl, Jessica said. There is a DNA match out there that is better than me and her dad. So we are relying on these good-hearted donors out there that put themselves on the registry and sign up to save a life.

Jessica said Paisleys sample is currently being run through the registry for a match. Jessica says they are hoping for a match to come through as early as the end of this year.

Theyre asking anyone who hears Paisleys story to register to see if they are a match to her or anyone going through blood cancer and other conditions.

Its helping me to see a positive purpose coming out of this devastating news, said Jessica, who has shared their journey to help educate others even more on Instagram. This cancer shows we all really need each other.

Right now, Jessica said Paisley is doing awesome with her treatments and continues to be a bright light for her mom and dad, nurses and doctors.

I am kind of feeding off of her own positivity, and Im happy to be able to share this awareness, said Jessica. Shes giving me the space to do that because shes being so strong herself.

Anyone between the ages of 18 and 40 can join the Be The Match registry by texting SavePaisley to 61474 or by clicking here.

Then, a cheek swab kit will be mailed to their home.

Be The Match covers the cost of transplants, including flights, hotels and meals. It also covers recipient costs that arent covered by insurance.

To find out more about registering or donating, click here.

See original here:
All really need each other: Family of 1-year-old Ohio girl with blood cancer waiting for bone marrow donor - WJW FOX 8 News Cleveland

VIDEO ABOVE: Jane Tiller discusses privacy issues surrounding online DNA tests. Watch full ep. here.

Karenne uploaded the data she received from her DNA test to a third party website. Her intention was to find out whether there were any hereditary medical issues in her family.

The very first thing that popped up was two BRCA genes, she told Insight. Which scared me quite considerably.

BRCA is an abbreviation for BReast CAncer gene. BRCA1 and BRCA2 are two different genes that have been found to impact a persons chances of developing breast cancer.

The first course of action for Karenne was to book an appointment with her doctor to talk through her genetic testing discovery. She wanted to get her doctors advice and find out if there was an option for further tests. My doctor pretty much said that it's too hard to be able to test the genes.

But Karenne decided to send her DNA to another direct consumer site for genetic health testing. The results came back with a different cancer gene.

Instead of just affecting breasts, it affects colon, bowel, breast, brain, skin, thyroid, there's a lot more to be concerned about.

After seeing a genetic counsellor Karenne did a colonoscopy at the age of 47. She discovered that she had polyps that may have been on the verge of becoming cancerous.

So by the time I turned 50 I would have already been fighting colon cancer.

Jane Tiller is an ethical, legal and social adviser in public health genomics at Monash University. She said there are few things people need to consider when they do genetic testing through a third party website. Privacy is one of them, she explained, adding that consumers dont know where their data will be sent and who will have access to it.

...People were given risk information that was actually inaccurate.

I think people don't always realise when they check a box to say yes, we'd like this to go to research that it's actually going to a pharmaceutical company for profit rather than maybe to a hospital for cancer research, she told Insight.

We don't always know which companies have those relationships and which don't, certainly in the terms and conditions they should say whether they'll share the data with third parties, whether they'll see your consent for it or not. Most people we know don't read terms and conditions.

Tiller said people also need to make sure the company theyre sending their data to for testing is a reputable company and that they receive accurate information.

A few years ago there was a study where they tried to validate results from interpretation websites and about 40 per cent of results were found to be false positives. People were given risk information that was actually inaccurate.

When you are not going through a clinically accredited genetic test you dont know whether the information you are getting back is accurate or not and whether you should be making decisions based on that.

Karenne is glad she did the test. She is now 50 years old and gets regular colonoscopies. She wants to get to the forefront of any health complication that may emerge. Due to her BRACA genes, (which had mutated increasing the risk of breast cancer) Karenne also underwent a double mastectomy in early 2021.

Im fully recovered now and more relieved and one less thing to worry about.

The rest is here:
How a genetic test led this woman to get a double mastectomy - SBS

FREMONT, Calif., Aug. 12, 2021 /PRNewswire/ -- The premium market intelligence report published by BIS Research on the title Global Direct-to-Consumer Genetic Testing Markethighlights that the market is projected to reach $6.60 billion by 2031. The study also highlights that the market is set to witness a CAGR of 17.30% during the period 2021-2031. The growth of the market is aided by rising government initiatives for the implementation of large sequencing initiatives coupled with the increasing requirement of genetic testing, including the current COVID-19 pandemic.

The global direct-to-consumer (DTC) genetic testing market consists of companies providing genetic testing services without the involvement of healthcare professionals. The DTC genetic testing companies offer genetics testing services for ancestry, health and wellness, and entertainment. Recent trends regarding extensive funding from various investors for the promotion of genetic testing are significantly propelling the market. Also, owing to the emerging concept of consumer empowerment, the global direct-to-consumer genetic testing market is witnessing a massive influx of new entrants in the industry.

Browse 04 Market Data Tables and 104 Figures spread through 187 Pages and in-depth TOC of the Global Direct-to-Consumer Genetic Testing Market Analysis and Forecast, 2021-2031.

The comprehensive study of the global direct-to-consumer genetic testingmarket by BIS Research covers the following:

Who should buy this report?

View the Report from BIS Research: Global Direct-to-Consumer Genetic Testing Market

To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include technology, business channel, product type, market share analysis, growth share analysis, and region. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.

The premium market intelligence by BIS Research additionally throws a spotlight on the opportunities existing in the market, including the higher adoption of genetic tests for early diagnosis of various chronic conditions such as cancer, prenatal screening, and infectious diseases, and increasing awareness among consumers regarding preventive healthcare.

The business channel and product analysis of the global market includes data analysis on the satisfaction level of different kits and services offered by the leading and emerging companies. The study is majorly centered on the sub-segments and micro-segments of the different product markets, such as ancestry, health and wellness, and entertainment.

To emphasize the dominance of the single nucleotide segment over whole genome sequencing under the technology category of direct-to-consumer genetic testing market in 2020 and 2031, Nitish Kumar Singh, Principal Analyst, BIS Research, states, "The reason for market growth can be attributed to the large-scale research and development along with several sequencing initiatives taken globally. The increasing disease burden, including the current COVID-19 pandemic, has led to large capital investments by key players along with the conscious efforts of the manufacturers to ensure data safety and quality of the results obtained after the test."

Request for a Sample: https://bisresearch.com/requestsample?id=1155&type=download

Key insights are drawn from in-depth interviews with the key opinion leaders of more than 15 leading companies, market participants, and vendors. The key players profiled in the report include 23andme, Inc., Ancestry.com LLC, 24Genetics, Atlas Biomed, Color Genomics, DNAfit, Gene by Gene, 10.9 Chengdu Twenty-Three Rubik's Cube Biotechnology Co., Ltd., Easy DNA, Mapmygenome, Laboratory Corporation of American Holdings, Myriad Genetics, Inc., Konika Minolta, Inc., and XCODE Lifescience, Inc.

The study also offers strategic recommendations that can help organizations track various products, trends, and technologies that are changing the market dynamics. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.

How can market intelligence on direct-to-consumer genetic test add value to an organization's decision-making process?

Insightful Questions Covered to Enable Companies take Strategic Decisions

Related Reports:

Global Molecular Diagnostics Point of Care Market - Analysis and Forecast, 2019-2029

Global Molecular Diagnostics Market Analysis and Forecast, 2018-2028

Global Single-Cell-Sequencing Market Analysis and Forecast, 2018-2029

About BIS Research:

BIS Research, a premium market intelligence company, offers in-depth insights and consulting to Fortune 500 companies. We are established and known for tracking the growth of deep technologies across key industry verticals and the subsequent challenges and opportunities associated with deep tech across markets, applications, and products.

With more than 1,000 clients, over 10,000 plus primary interviews, and approximately 200 reports published in a year, BIS Research has often been sighted for its ability to track emerging tech trends early on. We provide market estimations, analysis on emerging high-growth applications, technology analysis, highly segmented granular country-level market data, and other important market parameters that come in handy for our clients during strategic decision-making.

BIS Healthcare provides market-leading insights and data on lab-to-market and early-stage technologies such as precision medicine, robotics and imaging, life sciences and biopharma, and digital health. We have been celebrating the contribution of scientists, academicians, and industry researchers through our highly recognized compendiums Top 25 Voice, such as Healthcare Robotics, Precision Medicine, and Precision Medicine Asia.

Contact: Bhavya Banga Email: [emailprotected] BIS Research Inc. 39111 PASEO PADRE PKWY STE 313,FREMONT CA 94538-1686 Visit our Blog @ https://blog.bisresearch.com/Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research Connect with us on [emailprotected] https://twitter.com/BISResearch

SOURCE BIS Research

Visit link:
Global Direct-to-Consumer Genetic Testing Market to Reach $6.60 Billion by 2031, Says BIS Research Study - PRNewswire

New Jersey, United States,-The latest study on the industrial growth of the DTC Genetic Testing Market 2021-2028. A detailed study has been performed to provide the latest insight into the acute characteristics of the DTC Genetic Testing market. The report provides various market forecasts related to market size, revenue, production, CAGR, consumption, gross margin, price, and other critical factors. The report not only emphasizes the major driving and restraining forces in this market but also offers a comprehensive study of future trends and developments in the market. It also studies the roles of leading players in the industry market including their company overview, financial summary, and SWOT analysis.

This report analyzes the impact of the COVID-19 pandemic on market growth and sales. The report also includes an in-depth analysis of the current and future impact of the pandemic and post-COVID-19 scenario analysis.

Get | Download Sample Copy @ https://www.marketresearchintellect.com/download-sample/?rid=435683

The report provides a detailed analysis of the major market players along with an overview of their business, expansion plans, and strategies. The main actors examined in the report include:

DTC Genetic Testing Market: Key Catalysts

The market is further subdivided according to end-user type and application. The report also includes an assessment of the segment that is expected to be the market leader over the forecast years. The report provides detailed market segmentation by type and application along with historical data and forecast.

The report further studies the market segmentation based on the types of products offered in the market and their end-uses/uses.

While segmenting the Market by DTC Genetic Testing Types, the Report includes:

While segmenting the Market by DTC Genetic Testing Applications, the report covers the following application areas:

Ask for a Discount @ https://www.marketresearchintellect.com/ask-for-discount/?rid=435683

DTC Genetic Testing Market Report Scope

Due to the regional segmentation, the market is divided into the main regions North America, Europe, Asia-Pacific, Latin America, Middle East and Africa. In addition, the regional analysis covers the breakdown of the market and key players by country.

The research report offered by the Market Research Intellect provides an updated view of the global DTC Genetic Testing market. The report provides a detailed analysis of the key trends and emerging market factors that could affect the growth of the industry. Additionally, the report studies market features, competitive landscape, market size and growth, regional split, and strategies for this market.

DTC Genetic Testing Report Content Highlights:

DTC Genetic Testing World Market Review

Market competition from players and manufacturers

competitive environment

Production, estimate of sales by type and application

Regional analysis

Analysis of the industrial chain

Forecast of the world market DTC Genetic Testing

For more informative information, please visit us @ https://www.marketresearchintellect.com/product/global-dtc-genetic-testing-market-size-and-forecast/

Visualize DTC Genetic Testing Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment and Key players of your market. Present your Market Report & findings with inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize DTC Genetic Testing Market using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/

Thank you for reading our report. The report can be customized based on chapters or regions. Contact us to learn more about customization options and our team will make sure you generate a report based on your needs.

About Us: Market Research Intellect

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering customized and in-depth research studies.

Our advanced analytical research solutions, custom consulting and in-depth data analysis cover a range of industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages. Etc

Our research studies help our clients to make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information without compromise.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.Contact us:

Mr. Edwyne Fernandes

Market Research IntellectUS: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Website https://www.marketresearchintellect.com/

Read the original here:
DTC Genetic Testing Market Size, Analytical Overview, Growth and Forecast to 2028 - The Market Writeuo - The Market Writeuo

Lyndsay Willmott, MD, discussesthe importance of genetic testing in ovarian cancer.

Lyndsay Willmott, MD, gynecologic oncologist, Arizona Oncology, discussesthe importance of genetic testing in ovarian cancer.

When treating patients withovarian cancer, genetic testing is one of the easiest tools to incorporateinto clinical practice to help guide treatment decisions, according to Willmott. However, becausegenetic counselors are scarcein some areas, it is importantto be an informed advocate for genetic testing so that its use is initiated in the frontline, Willmott says.Additionally,educating patients on the importance of genetic testing can serve to overcome hesitancy and empower them with respect to treatment decisions, Willmott adds.

Moreover, it has been shown that patients with a BRCA mutation may perform better with certain agents, according to Willmott. Although this might not be universal, it is important to counsel patients about the link between mutational status and their available treatment options,Willmott says.Sharing this information with patients will help them to manage expectations regarding their treatment journey and empower them through the clinical decisions that are being made, Willmott concludes.

Follow this link:
Dr. Willmott on the Importance of Genetic Testing in Ovarian Cancer - OncLive

The Latest Released Preimplantation Genetic Testing Market study has evaluated the future growth potential of Global Preimplantation Genetic Testing market and provides information and useful stats on market structure and size. The report is intended to provide market intelligence and strategic insights to help decision makers take sound investment decisions and identify potential gaps and growth opportunities. Additionally, the report also identifies and analyses changing dynamics, emerging trends along with essential drivers, challenges, opportunities and restraints in Preimplantation Genetic Testing market. The study includes market share analysis and profiles of players such as Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Inc., Beijing Genomics Institute (BGI), Abbott Laboratories, Natera, Inc., Genea Limited, Rubicon Genomics, Inc. and Oxford Gene Technology

If you are a Preimplantation Genetic Testing manufacturer and would like to check or understand policy and regulatory proposal, designing clear explanations of the stakes, potential winners and losers, and options for improvement then this article will help you understand the pattern with Impacting Trends.

Major Highlights of the Preimplantation Genetic Testing Market report released by Adroit Market Research

Market Breakdown by Applications: .

Market Breakdown by Types: by Test Type (Aneuploidy, Structural Chromosomal Abnormalities, Single Gene Disorders, X-linked Disorders, HLA Typing, Gender Identification) and Technology (Next Generation Sequencing, Polymerase Chain Reaction, Fluorescent In-Situ Hybridization, Comparative Genomic Hybridization, Single Nucleotide Polymorphism)

Revenue and Sales Estimation Historical Revenue and sales volume is presented and further data is triangulated with top-down and bottom-up approaches to forecast complete market size and to estimate forecast numbers for key regions covered in the report along with classified and well recognized Types and end-use industry.

SWOT Analysis on Preimplantation Genetic Testing Players

In additional Market Share analysis of players, in-depth profiling, product/service and business overview, the study also concentrates on BCG matrix, heat map analysis, FPNV positioning along with SWOT analysis to better correlate market competitiveness.

Demand from top notch companies and government agencies are expected to rise as they seek more information on latest scenario. Check Demand Determinants section for more information.

Regulation Analysis

Local System and Other Regulation: Regional variations in Laws for the use of Preimplantation Genetic Testing

Regulation and its Implications

Other Compliances

FIVE FORCES & PESTLE ANALYSIS:

In order to better understand Preimplantation Genetic Testing Market condition five forces analysis is conducted that includes Bargaining power of buyers, Bargaining power of suppliers, Threat of new entrants, Threat of substitutes, Threat of rivalry.

Political (Political policy and stability as well as trade, fiscal and taxation policies)

Economical (Interest rates, employment or unemployment rates, raw material costs and foreign exchange rates)

Social (Changing family demographics, education levels, cultural trends, attitude changes and changes in lifestyles)

Technological (Changes in digital or mobile technology, automation, research and development)

Legal (Employment legislation, consumer law, health and safety, international as well as trade regulation and restrictions)

Environmental (Climate, recycling procedures, carbon footprint, waste disposal and sustainability)

Heat map Analysis, 3-Year Financial and Detailed Company Profiles of Key & Emerging Players:Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Inc., Beijing Genomics Institute (BGI), Abbott Laboratories, Natera, Inc., Genea Limited, Rubicon Genomics, Inc. and Oxford Gene Technology

Geographically, the following regions together with the listed national/local markets are fully investigated:

APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)

Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)

North America (U.S., Canada, and Mexico)

South America (Brazil, Chile, Argentina, Rest of South America)

MEA (Saudi Arabia, UAE, South Africa)

Global Preimplantation Genetic Testing Market Size (Sales) Market Share by Type (Product Category) [, Lifetime Preimplantation Genetic Testing, Regular Preimplantation Genetic Testing, Union Preimplantation Genetic Testing & Variable Preimplantation Genetic Testing] in 2020

Preimplantation Genetic Testing Market by Application/End Users []

Global Preimplantation Genetic Testing Sales and Growth Rate (2015-2028)

Preimplantation Genetic Testing Competition by Players/Suppliers, Region, Type and Application

Preimplantation Genetic Testing (Volume, Value and Sales Price) table defined for each geographic region defined.

Supply Chain, Sourcing Strategy and Downstream Buyers, Industrial Chain Analysis

..and view more in complete table of Contents

About Us

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us:

Ryan Johnson

Account Manager Global

3131 McKinney Ave Ste 600, Dallas,

TX75204, U.S.A.

More:
Dissecting Growth Strategies for Preimplantation Genetic Testing Market by Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer -...

New Jersey, United States,-Verified Market Research recently released a new report titled DTC Genetic Testing MarketSize Report, Growth and Forecast 2021-2028, Breakdown Data by Company, Key Regions, Types and Applications. The report has been compiled using primary and secondary research methodology that will provide a precise and precise understanding of the DTC Genetic Testing market. Analysts used a top-down and bottom-up approach to assess the segments and properly assess their impact on the DTC Genetic Testing market. The report offers a market overview which briefly describes the market situation and major segments. It also mentions the best players represented in the DTC Genetic Testing market.

The 2021 report offers an in-depth analysis of each sector of this DTC Genetic Testing industry. Fill in historical DTC Genetic Testing data according to customer requirements. It offers DTC Genetic Testing market research globally and locally. The detailed segment and manufacturer information of DTC Genetic Testing helps guide future benefits and make important decisions for the growth of DTC Genetic Testing.

Get | Download Sample Copy with TOC, Graphs & List of Figures @https://www.verifiedmarketresearch.com/download-sample/?rid=12309

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Full Genomes Corporation Quest Diagnostics, Myriad Womens Health Inc., Gene By Gene, Ltd., Positive Biosciences Ltd., 23andMe, Inc.

DTC Genetic Testing Market Segmentation

DTC Genetic Testing Market by Test Type

Carrier Testing Predictive Testing Nutrigenomic Testing Ancestry & Relationship Testing Others

DTC Genetic Testing Market by Technology

Targeted analysis Single nucleotide polymorphism (SNP) chips Whole genome sequencing (WGS)

In the next chapters, the research report reveals the development of the DTC Genetic Testing market segments. Analysts have segmented the market on the basis of product, application, end-users, and geography. Each segment of the DTC Genetic Testing market has been studied with in-depth insight. Analysts have evaluated the changing nature of the market segments, growing investments in manufacturing activities, and product innovation that are likely to impact them. In terms of geography, the report studies the changing political environment, social upliftment, and other government initiatives that are expected to contribute to the regional markets.

Get Discount On The Purchase Of This Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=12309

DTC Genetic Testing Market Report Scope

Geographic Segment Covered in the Report:

North America (USA and Canada) Europe (UK, Germany, France and the rest of Europe) Asia Pacific (China, Japan, India, and the rest of the Asia Pacific region) Latin America (Brazil, Mexico, and the rest of Latin America) Middle East and Africa (GCC and rest of the Middle East and Africa)

Key questions answered in the report:

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/dtc-genetic-testing-market/

Visualize DTC Genetic Testing Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize DTC Genetic Testing Market using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: [emailprotected]

Website:- https://www.verifiedmarketresearch.com/

Go here to read the rest:
DTC Genetic Testing Market Size By Type, Application Analysis, Key opportunities and challenges - The Market Writeuo - The Market Writeuo

As per the latest report by IMARC Group, titled Preimplantation Genetic Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026, the global preimplantation genetic testing market exhibited XX growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2021-2026. Preimplantation genetic testing (PGT) detects abnormal embryos and facilitates the transfer of genetically normal embryos. It also reduces the trauma of several failed in vitro fertilization (IVF) cycles and early miscarriages. Moreover, PGT is used to treat individuals with high chances of having babies with specific genetic aberrations, as it protects children from inherited monogenic disorders. Apart from this, it is utilized in hematological disorders in children and in cases of advanced maternal age to prevent the birth of a syndromic child.

Request Free Sample Report: https://www.imarcgroup.com/preimplantation-genetic-testing-market/requestsample

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Preimplantation Genetic Testing Market Trends:

Rising birth rates and incidences of spontaneous miscarriages are some of the primary factors positively influencing the demand for PGT to minimize the need for multiple IVF cycles. Additionally, the growing risks of miscarriage with the womans age, along with the emerging trend of delayed parenthood is further strengthening the global market. Besides this, the expanding medical tourism sector and improving diagnostic modalities are also bolstering the market growth. Moreover, the introduction of innovative techniques, such as microarray and genome sequencing, coupled with the escalating demand for minimally invasive (MI) procedures, is positively influencing the market. Furthermore, the rising integration of PGT technology with Assisted Reproductive Technology (ART) procedures to offer improved outcomes to patients is expected to drive the global PGT market in the coming years.

Explore Full Report with TOC & List of Figure: https://bit.ly/3zUV5Wk

Key Market Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:

Breakup by Product:

Breakup by Procedure:

Breakup by Technology:

Breakup by Application:

Breakup by Region:

Key highlights of the Report:

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Contact US

IMARC Group 30 N Gould St, Ste RSheridan, WY (Wyoming) 82801 USA Email: [emailprotected]Tel No:(D) +91 120 433 0800Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

See original here:
Preimplantation Genetic Testing Market: Demand, Trends and Business Opportunities 2021-26 - The Market Writeuo - The Market Writeuo

Beverly Theil| Columnist

August is Child Support Awareness Month. Please be aware there are both dead beat moms as well as dead-beat dads. Lets look at how child support occurs.

More: ABOUT CHILDREN: It can't be said enough - have your children vaccinated

First, a relationship between the parent and child must be established. Maternity is established by the mother giving birth. Paternity is established several ways. If a couple is married at the time of a childs birth the husband is presumed to be the father. If the parents are not married, there is a voluntary acknowledgment process through completion of the Acknowledgment of Paternity Affidavit."

This form can be completed at the hospital when the child is born, before both parents leave the hospital, or it can be completed at your county's Child Support Enforcement Agency (CSEA) or your local Vital Statistics Registrar.

If the paternity of a child is contested or in doubt either parent may request the CSEA conduct DNAtesting to determine paternity. All parties are ordered to submit to genetic testing.

An administrative paternity order is issued based on the outcome of the genetic test, which must show at least a 99% probability of fatherhood. If either parent fails to submit to the test, or fails to submit the child for genetic testing, the CSEA may request the court to find the party in contempt and force compliance.

After paternity is established the CSEA schedules a support hearing to establish a support order for the child. Establishment of paternity refers to the legal determination of parentage, not the childs last name.

If the mother has given the child her last name and the father wants the child to have his last name but they do not agree, the father must go to court to have the name changed.

The process to establish paternity is available at any time before the child becomes 23 years old. Paternity can be established even if the parents live in different states or different countries.

A person may receive support if they are the child's biological parent, guardian, legal custodian or other person with whom the child lives. Support orders can sometimes be established by the CSEA without going to court but, if necessary, the CSEA will assist in obtaining a child support order.

The amount of support is determined by using the Ohio Child Support Guidelines. Both parents must provide verification of their incomes for the past six months or their most recent income tax returns. If the obligor (parent who owes support) doesnt pay the state may use income withholding.

This applies to not just wages and includes, but is not limited to: personal earnings; workers' compensation payments; unemployment compensation benefits; pensions; annuities; allowances; private or governmental retirement benefits; disability or sick pay; insurance proceeds; lottery prize awards; any form of trust fund or endowment; lump-sum payments; assets in a financial institution; any other payment in money.

They also can use the Tax Offset, the collection of state and federal tax refunds. Also they can report the support debt to the credit bureaus, invoke professional license suspension, increase the amount of income withholding to pay arrears; and get a seek work orderfor the parent.

Failure to comply with a child support order can result in contempt of court charges. Penalties can increase and include fines and/or jail time. Federal law provides for criminal non-support charges.

In certain cases that includes imprisonment for up to six months and/or a fine, and mandatory restitution of the unpaid support.

Be a good parent. Pay your child support.

Beverly Theil is a child advocate who lives in Ohio. She can be contacted at BeverlyVT@aol.com.

See more here:
ABOUT CHILDREN: A look at how child support works and the Child Support Enforcement Agency - Wooster Daily Record

The Hill may be compensated and/or receive an affiliate commission if you buy through our links.

Many of us have been spending more time than ever with our pets during the past year of stay-at-home lifestyles, and perhaps, by now, you've become just as curious about your dog as he seems to be about, well, everything.

We've got you covered in those efforts to discover more about what makes your furry friend special, along with ways to ensure they're living their best life possible. The All-in-One DNA My Dog Breed Identification Test & Dog Training Bundle is a comprehensive package primed to create better pet owners and happier animals.

Typically priced at more than $1,200, a limited-time discount currently drops that cost to only $59.99. The value has never been higher for this unique bundle.

To begin, the DNA My Dog Breed Identification Test is an at-home genetics test that requires only a simple mail-in process. This innovative kit will help you learn all about your pup's breed, health tendencies, natural traits, and unique habits.

Not only is this an easy way to uncover cool facts about your pet, but it's also an important step toward ensuring they experience a long, fulfilling life. This report includes a breakdown of breed composition, behavioral insights, hereditary health risks and potential links, and helpful suggestions.

This process is proven and earned recognition among Leaders in Ethical Canine Genetic Testing at the 2020 GHP Biotechnology Awards. And don't worryyour buddy won't need to deal with any pain along the way.

All that's necessary is a gentle swab, which is then sent back in a prepaid envelope. Soon afterward, a detailed report will be returned to you.

With this bundle, you will also gain unlimited access to eight courses that span 12 total hours. These easy-to-use educational guides detail need-to-know information on diets, leash use, and behavior.

You'll also gain insight into starting and sustaining a successful dog training business that benefits both you and any potential list of clients. Plus, discover the leading methods to raising a healthy, happy, and obedient puppy.

Take advantage of this deal and get to know your dog in greater detail than you've ever imagined by purchasing The All-in-One DNA My Dog Breed Identification Test & Dog Training Bundle for only $59.99 (reg. $1,239).

Prices subject to change.

View post:
Improve your dog's health and training with this low-cost bundle | TheHill - The Hill

CLEVELAND There is promising new research out of Cleveland thats giving hope to people around the world who are facing a terrifying future.

Jesse Lis lost her dad, Michael, in April of 2020. He was 64.

More painful, she says, was watching him die for more than a decade from Huntingtons Disease.

It is so scary to watch someone who was so perfect your whole life to deteriorate to nothing, to someone who's unable to walk, talk or even reason, said Lis. That's a really hard blow.

Another heavy blow is realizing it'll happen to you, too.

Huntingtons Disease is a fatal, progressive brain disease often described as having ALS, Parkinson's and Alzheimer's all at the same time.

It is genetic. A child of a parent with Huntingtons has a 50/50 chance of inheriting the faulty gene. Jesse and her family did genetic testing after her fathers diagnosis in 2008 and discovered the disease was pervasive in their family tree.

Jesse has it and knows the cruel fate that awaits. She is 40 years oldin the prime of her life right when it usually hits.

Every day I wake up and think, 'Is today the day that I'm going to trip and fall?' or 'Is today the day where I won't remember something really important?'"

It is a lot to cope with, but Jesse fights to stay positive and works hard to raise money and awareness as the president of the Northeast Ohio chapter of the Huntingtons Disease Society.

I am one of those people who isn't going to stop until I can save others and until I can save my family, she said.

Right now, there is no treatment to prevent or slow Huntingtons Disease, but new research at Case Western Reserve University could help change that.

This really surprised us when we saw the data, said Dr. Xin Qi.

Xin Qi and her team just discovered a potential breakthrough in how to prevent and slow the neuron degeneration that causes Huntingtons disease. She says this treatment is safer and more targeted than previous therapies. It is early, she cautions and says more research and clinical trials are still needed.

If our strategy demonstrates to be useful and safe to patients, I will say best of luck, within five years we may make some breakthrough, she said.

With an estimated 41,000 Americans being symptomatic, and 200,000 at-risk of inheriting Huntingtons, according to the Huntington Disease Society, the findings offer hope that families like Jesses are desperate for.

Its not fair that a fatal brain diagnosis should impact every generation, she said. It's just not fair.

You are invited to help these families. The Team Hope Walk is Sunday, Aug. 15 at the Cleveland Metroparks Zoo. Registration starts at 7 a.m. The 5k starts at 8:30 a.m. and the walk starts at 9 a.m.

The money raised helps pay for social workers for families and also helps fund research for a cure and treatments.

Click here for more info.

Download the News 5 Cleveland app now for more stories from us, plus alerts on major news, the latest weather forecast, traffic information and much more. Download now on your Apple device here, and your Android device here.

You can also catch News 5 Cleveland on Roku, Apple TV, Amazon Fire TV, YouTube TV, DIRECTV NOW, Hulu Live and more. We're also on Amazon Alexa devices. Learn more about our streaming options here.

Read more:
How a local woman continues to fight despite a grim prognosis, and the promising research to cure Huntington's Disease - News 5 Cleveland

Request Download SampleAsk For DiscountCompany Profile

New Jersey, USA,"Global Breast Cancer Predictive Genetic Testing Market Analysis to 2028" is a professional and in-depth industry study with a particular focus on analyzing global market trends. The report aims to provide an overview of the next-generation clinical sequencing market with detailed market segmentation by type, application, and region. The report provides key statistics on the market status of key Breast Cancer Predictive Genetic Testing market players and provides key trends and opportunities in the market.

In addition, the global Breast Cancer Predictive Genetic Testing Market is expected to grow at a CAGR of about XX % over the next five years, will reach XX Billion US $in 2020, XX Billion US $in 2028

Get | Download Sample Copy with TOC, Graphs & List of Figures @https://www.marketresearchintellect.com/download-sample/?rid=230278

Competitor Analysis

The competitive landscape is an important aspect that every key player should be familiar with. The report throws light on the competitive scenario of the global Breast Cancer Predictive Genetic Testing market to know the competition at both domestic and global levels. Market experts also provide an overview of all the leading players of the global Breast Cancer Predictive Genetic Testing market, considering key aspects such as local operations, production, and product portfolio. In addition, the company's report is based on research key factors such as the company's size, market share, market growth, income, output, and profit.

The research focuses on the current market size of the Breast Cancer Predictive Genetic Testing market and its growth rates based on records with the company outlines of key players/manufacturers:

The major players covered in Breast Cancer Predictive Genetic Testing Markets:

Market segmentation of Breast Cancer Predictive Genetic Testing market:

Breast Cancer Predictive Genetic Testing market is divided by type and application. For the period 2021-2028, cross-segment growth provides accurate calculations and forecasts of sales by Type and Application in terms of volume and value. This analysis can help you grow your business by targeting qualified niche markets.

Breast Cancer Predictive Genetic Testing Market breakdown by Type:

Breast Cancer Predictive Genetic Testing Market breakdown by application:

Get Discount On The Purchase Of This Report@https://www.marketresearchintellect.com/ask-for-discount/?rid=230278

Breast Cancer Predictive Genetic Testing Market Report Scope

Regional market analysis Breast Cancer Predictive Genetic Testing can be represented as follows:

Each regional Breast Cancer Predictive Genetic Testing sectors is carefully studied to understand its current and future growth scenarios. This helps players to strengthen their position. Use market research to get a better perspective and understanding of the market and target audience and ensure you stay ahead of the competition.

The base of geography, the world market of Breast Cancer Predictive Genetic Testing has segmented as follows:

For More Information or Query or Customization Before Buying, Visit @https://www.marketresearchintellect.com/product/global-breast-cancer-predictive-genetic-testing-market-size-and-forecast/

Visualize Breast Cancer Predictive Genetic Testing Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform to tell the story of this market. VMI provides in-depth predictive trends and accurate insights into more than 20,000 emerging and niche markets to help you make key revenue impact decisions for a brilliant future.

VMI provides a comprehensive overview and global competitive landscape of regions, countries, and segments, as well as key players in your market. Showcase your market reports and findings with built-in presentation capabilities, providing more than 70% of time and resources for investors, sales and marketing, R & D, and product development. VMI supports data delivery in Excel and interactive PDF formats and provides more than 15 key market indicators for your market.

Visualize Breast Cancer Predictive Genetic Testing Market using VMI @hhttps://www.marketresearchintellect.com/mri-intelligence/

The study explores in depth the profiles of the main market players and their main financial aspects. This comprehensive business analyst report is useful for all existing and new entrants as they design their business strategies. This report covers production, revenue, market share and growth rate of the Breast Cancer Predictive Genetic Testing market for each key company, and covers breakdown data (production, consumption, revenue and market share) by regions, type and applications. Breast Cancer Predictive Genetic Testing historical breakdown data from 2016 to 2020 and forecast to 2021-2029.

About Us: Market Research Intellect

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations in addition to the objective of delivering customized and in-depth research studies.

We speak to looking logical research solutions, custom consulting, and in-severity data analysis lid a range of industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages. Etc Our research studies assist our clients to make higher data-driven decisions, admit push forecasts, capitalize coarsely with opportunities and optimize efficiency by bustling as their belt in crime to adopt accurate and indispensable mention without compromise.

Having serviced on the pinnacle of 5000+ clients, we have provided expertly-behaved assert research facilities to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony, and Hitachi.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Website: https://www.marketresearchintellect.com/

Originally posted here:
Breast Cancer Predictive Genetic Testing Market To Observe Exponential Growth By 2021-2028 | Roche, Thermo Fisher Scientific, PerkinElmer, Quest...

A Wadsworth woman was reunited with a son she put up for adoption33 years ago.

Beacon Journal partner News 5 Cleveland reports that the woman found her son through 23andMe, a DNA genetic testing service.

Melanie Pressley told News 5 that she was 18 when she was pregnant with her first son. She knew she couldn't take care of him financially, and she wanted him to have a mom and dad, so she put him up for adoption through an agency in Akron.

She gave birth to him in 1988, which was the last time she saw her son.

News 5 reports that her son, Greg Vossler, was adopted by a family in Stow. At age 7, he and his family moved to Winchester, Virginia.

Pressley had gone on to become happily married and had more children, but she always wondered about her son, she told News 5. Eventually, Vossler also wanted to know more about his biological parents.

He took a 23andMe test in 2019. She took one in May 2021, and the tests matched them together.

Instantly sent a message, and my first message wasI believe we're related, said Pressley. The next message wasI believe I am your birth mother. And from there it just blew up.

One of the very first questions I asked him, which was big for me, was, Are you happy? And he came back that he was oh, my gosh that he's married, he has two boys. I mean, it was just like spilling everything, Pressley said.

In June, the two met in Wadsworth and saw each other for the first time in 33 years.

Vossler told News 5 thathe and Pressley talked for four hours straight that first day. He also met 17 members of his new extended family.

Everyone's emotional, everyone's shaking hands or hugging. And, you know, Hey, I'm your half-brother, your half-sister. And her oldest sister, who was instrumental in allowing Melanie to have that first picture, came up and grabbed my face. The first time in 33 years that she's seen me, Vossler said.

It's an amazing feeling. And it just goes to show that there's always room for families to grow and always room for more love within each other, Vossler said.

The two are continuing to nurture their new relationship, News 5 said, with Pressley planning to visit Vossler in Virginia soon.

Read more about the story from News 5 Cleveland here.

Read the original:
Wadsworth woman reunited with son she put up for adoption after 33 years - Akron Beacon Journal